Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants With Type 2 Diabetes

NCT06254274 is registered in ClinicalTrials.gov with Guangdong Raynovent Biotech Co., Ltd as lead sponsor.

NCT NCT06254274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06254274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants With Type 2 Diabetes
Lead sponsor
Guangdong Raynovent Biotech Co., Ltd
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 26, 2024
Completion date
December 20, 2025
Enrollment
210 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

t2dm (type 2 diabetes mellitus)